Zimmer price target raised to $113 from $105 at Cantor Cantor increased its price target on Zimmer after the company agreed to buy Biomet. The firm thinks that, beginning in the second year of the deal, Zimmer's accretion guidance could be slightly conservative. It keeps a Buy rating on the stock.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.